Therapeutic solutions for neurodegeneration


There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.

Alzprotect designs and develops innovative therapeutic solutions for these diseases.

Our objective: to slow down or stop neurodegeneration and, where possible, to restore some brain capacities

 Learn more about Alzprotect 

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.

Schematic diagram of the action of AZP2006

Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.

Learn more about
AZP2006 molecule

News

Alzprotect Completes Phase 2a Clinical Trial Enrollment for AZP2006 in Progressive Supranuclear Palsy (PSP)

Lille (France), January 20th, 2022 – ALZPROTECT, a biopharmaceutical company developing treatments for neurodegenerative diseases, today announced it has completed patient enrollment for the Company’s phase 2a clinical trial evaluating its platform asset, AZP2006 (“EZEPROGIND”) in Progressive Supranuclear Palsy (PSP), a rare neurodegenerative disorder which seriously impacts walking, balance, eye movement, and in the latter stage of the disease, the ability to swallow. This PSP trial, which is part of a multi-indication development plan for AZP2006, has recruited thirty-six patients and is being conducted at the Pitié-Salpêtrière University Hospital of Paris, the University Hospital of Lille, and the Hospital Foundation Adolphe de Rothschild. For PSP, AZP2006 has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). It was tested on 102 healthy human subjects throughout three phase I clinical trials and reported excellent tolerability, with no adverse effects.

“This is an important milestone for the company and of course, the PSP patient community who are suffering from this debilitating disease where there are no treatment options currently available, “commented Philippe Verwaerde, CEO of Alzprotect. “All of us involved with the development of AZP2006 are excited by its potential to be used as standalone therapy in early disease, and for its being able to be combined easily with other agents as neurodegenerative diseases progress fast. At the time when novel neurology agents are coming under acute reimbursement scrutiny, a simple modality like AZP2006 makes good sense as an addition to the treatment armamentarium in neurodegenerative diseases. As such this Phase 2A in PSP will serve as an excellent proxy for patient tolerability and early efficacy signals for this drug candidate.”

Alzprotect is developing AZP2006 (EZEPROGIND), an orally available small molecule which has demonstrated that it can augment the functional half-life of Progranulin in the brain to help restore microglia homeostasis in neurodegenerative diseases. By modulating Progranulin through its cognate lysosome-trafficking chaperone protein, Prosaposin, AZP2006 works through a novel mechanism of action from other Progranulin-inducing agents in clinical development so far. Due to its nuanced control of Progranulin, AZP2006 can be used to treat a variety of neurodegenerative diseases and does not have to limited to one/few indications. Upon evaluation of the results from the Phase 2A PSP trial, the Company will launch a US IND for a randomized Phase 2B/3 trial in this indication.  Also, as part of its multi-indication drug development plan additional trials in three new indications, GBA-1 Parkinson’s disease, Alzheimer’s disease and Amyotrophic lateral sclerosis will be launched by 2023.

About the Phase 2a study with EZEPROGIND in PSP

The primary objective of this clinical trial is to evaluate the tolerability of the product in PSP patients; to strengthen the pharmacokinetic (PK) and pharmacodynamic (PD) data of the product after 3 month-treatment; and to evaluate the impact of the treatment on the disease’s markers (more than 20 of them, targeting inflammation and neurodegeneration). This Phase 2a study is expected to be completed by July 2022 with top-line results published in Q3 2022. As part of the trial, 36 PSP patients receive a placebo or one of two EZEPROGIND doses which are administered orally for 3 months, followed by a 3-month observation period.

Efficacy endpoints include PK/PD evaluation of AZP2006 in patients, biomarker data across a panel of chosen biomarkers, and evaluating four-different PSP rating scales to be used in subsequent and registrational trials.

 

About Progressive Supranuclear Palsy (PSP)

PSP is a tauopathy with predominant accumulation of Tau isoforms with four repeat motifs (4R). It is characterized by neurofibrillary degeneration and neuronal loss in the brainstem, basal ganglia, frontal motor and associative cortex. The disease causes brainstem damage that progressively affects balance, vision, mobility, swallowing and speech. The number of PSP cases in Europe and the United States is estimated at 30,000 and 25,000, respectively. The average life expectancy of PSP patients ranges from 5 to 7 years.

About Alzprotect

Alzprotect imagines and develops therapeutic solutions to slow down or stop neurodegenerative diseases and restore patients’ brain capacity. Founded in 2007, Alzprotect is a French Lille-based company created by Dr. André Delacourte, one of the pioneers of research on Alzheimer's disease, and Dr. Patricia Melnyk, expert in medicinal chemistry, in collaboration with Lille 2 University and INSERM. The company employs 8 people and is supported by BPI France, the National Research Agency and Eurasanté. Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases. Alzprotect has 4 international patent families covering the medicines it develops and their indications worldwide.

For more information: http://www.alzprotect.com/enpage LinkedIncorporate video -  Ezeprogind MOA video

***

Contact:

ALZPROTECT                                                                                

Dr Philippe Verwaerde, PhD                                                                                 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Alzprotect strengthens its Board of Directors with the arrival of Dr. John Tchelingerian

 

Lille (France), June 22nd, 2021 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today that Dr. John Tchelingerian has joined the Board of Directors of Alzprotect. Alzprotect is financed by the Xerys Funds.

 

Dr John Tchelingerian is a serial entrepreneur in life sciences. As a veteran of the industry, he co-founded and/or lead several biotech companies as CEO or Chairman & CEO. He raised a total of over €200 million of funding during his career and achieved together with his teams to bring five drug candidates from research to the clinics (up to phase IIb/III) and realized several international pharmaceuticals partnering and M&A deals. He is currently the Managing Partner and co-founder of two specialized strategic advisory firms, The Connecting Architects and Silver Ocean Ventures and Chairman of Pan-Cancer T’s Supervisory Board. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris.

Dr. John Tchelingerian commented:  « I am delighted joining the board of Alzprotect as a Director to contribute to the company’s growth and its success. The company has made remarkable progress since the first time I met Philippe and his team a few years ago. I am convinced that Alzprotect will be a game changer in the field of PSP with its drug-candidate AZP-2006, currently in phase 2a clinical trials in Europe. »

Dr Philippe Verwaerde, President of Alzprotect, declared: "John's profile and experience are valuable assets to strengthen our board of directors on the eve of a strategic inflection point and a rise in development of Ezeprogind / AZP2006 "

 

All news